Octri-Lar – sayretherapeutics

OCTRI-LAR® Depot

Octreotide Long-acting Release Injection (Powder and Solvent for Suspension) 20mg / 30mg

For Long-term treatment of the severe diarrhoea and flushing episodes associated with metastatic carcinoid & VIP-secreting tumors.

Indication

OCTRI-LAR^®Depot is indicated in patients in whom initial treatment with octreotide acetate Injection has shown to be effective and tolerated for:

Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors.

Formulation

OCTRI-LAR^®Depot should be administered intramuscularly in the gluteal region at 4-week intervals.

OCTRI-LAR®Depot

Is a long acting, synthetic protein similar to a hormone in the human body called somatostatin.
Provides symptomatic control (in carcinoid & VIP-secreting tumors).
Helps in reducing the risk of disease progression in NET.
Provides superior patient compliance.

OCTRI-LAR^®Depot uses PLGA microspheres for drug delivery, they are glucose initiated poly (D,L-Lactide-co-glycolide) microspheres which benefit in controlled drug release in the body over a longer duration of time

OCTRI-LAR® Depot

Octreotide Long-acting Release Injection (Powder and Solvent for Suspension) 20mg / 30mg

Quick Link

Get in Touch

OCTRI-LAR® Depot

Octreotide Long-acting Release Injection (Powder and Solvent for Suspension) 20mg / 30mg

Quick Link

Get in Touch

Contact Us